Related Experiment Video
Updated: May 5, 2026
07:20
Author Spotlight: Repetitive Transcranial Magnetic Stimulation Combined with Movement Observation in Cerebral Palsy
Published on: August 9, 2024
3.0K
HUS and TTP in Children
1Division of Nephrology, Department of Pediatrics, CTSI, NYU Langone Medical Center, 227 East 30th Street, Room #110, New York, NY 10016, USA.
Pediatric Clinics of North America
|November 19, 2013
Summary
This review covers pediatric thrombotic microangiopathy, focusing on hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. It details their causes, symptoms, treatments, and long-term outcomes for affected children.
Area of Science:
- Pediatric Hematology
- Nephrology
- Critical Care Medicine
Background:
- Thrombotic microangiopathy (TMA) encompasses serious conditions affecting small blood vessels.
- Hemolytic uremic syndrome (HUS) and thrombotic thrombocytopenic purpura (TTP) are the primary pediatric TMAs.
Purpose of the Study:
- To provide a comprehensive overview of pediatric TMAs.
- To consolidate current knowledge on HUS and TTP epidemiology, pathophysiology, and clinical management.
Main Methods:
- Systematic literature review of pediatric TMA cases.
- Analysis of epidemiological data, clinical presentations, and etiological factors.
- Evaluation of treatment strategies and prognostic indicators.
Main Results:
- Detailed description of TMA incidence and risk factors in children.
- Elucidation of the pathophysiological mechanisms underlying HUS and TTP.
- Summary of diagnostic criteria and therapeutic approaches, including supportive care and specific treatments.
Conclusions:
- Early recognition and prompt management are crucial for improving outcomes in pediatric TMA.
- Understanding the specific phenotypes of HUS and TTP guides tailored treatment strategies.
- Long-term follow-up is essential to monitor for sequelae in pediatric patients surviving TMA.
Keywords:
Alternative pathway of complement (APC)Hemolytic uremic syndrome (HUS)Shiga toxin (Stx)Thrombotic microangiopathy (TMA)Thrombotic thrombocytopenic purpura (TTP)More Related Videos
Related Concept Videos
01:29Hepatic Encephalopathy
71
DefinitionHepatic encephalopathy is a reversible neurologic syndrome that results from advanced liver dysfunction or portosystemic shunting. It leads to disturbances in cognition, behavior, and motor function due to the brain’s exposure to gut-derived toxins that the liver fails to detoxify.EtiologyThis condition develops either in the setting of acute fulminant hepatitis or progressively during chronic liver disease, such as cirrhosis and portal hypertension. Portosystemic...
71
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
414
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
414
01:21Huntington Disease l: Introduction
166
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show...
166
01:25Urinary Tract Infection II: Pathophysiology
1.5K
The pathophysiology of urinary tract infections (UTIs) encompasses several progressive stages, beginning with bacterial colonization and culminating in potential systemic complications if untreated. UTIs are primarily initiated by bacteria, such as Escherichia coli, which often originate from the gastrointestinal tract and migrate to the urinary system through the periurethral area. This migration can occur via several routes, including improper hygiene practices, sexual activity, or...
1.5K
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
975
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
975
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
413
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
413